Cartalax vs EGF

Tetrapeptide bioregulator from cartilage tissue; stimulates chondrocyte proliferation and extracellular matrix synthesis; normalizes gene expression in cartilage cells

Cartalax is a Khavinson-class short bioregulator peptide investigated for connective tissue and cartilage maintenance. Like other ultrashort peptides in this research category, cartalax is proposed to reach musculoskeletal target cells via amino acid transporter mechanisms and influence gene expression pathways associated with cellular aging. Published preclinical studies of structurally related Khavinson peptides show regulation of aging-associated genes and epigenetic markers in mesenchymal stem cell models. Human clinical evidence specific to cartalax is limited; existing research is predominantly preclinical and based on related peptides within the same class. Cartalax benefits investigated in preclinical research include support for chondrocyte proliferation, extracellular matrix synthesis, and cartilage tissue homeostasis — areas relevant to age-related joint degeneration, osteoarthritis research, and connective tissue maintenance. As a bioregulator peptide, cartalax is proposed to work by modulating gene expression in cartilage-specific cells rather than providing direct structural repair, distinguishing it mechanistically from direct injections of growth factors or PRP. Research interest also extends to combined bioregulator protocols pairing cartalax with other Khavinson-class peptides targeting musculoskeletal and connective tissue health, including protocols used alongside cortagen for vascular-connective tissue support. Cartalax dosage: No human clinical trial has established a reference dose for cartalax. Preclinical research protocols in the Khavinson bioregulator literature have examined peptide bioregulators at doses in the microgram-to-low-milligram range via subcutaneous injection, typically administered in defined cycles. Oral bioregulator formulations of related Khavinson peptides have also been studied. Cartalax is a research compound with no approved human dosing guidelines.

Binds EGFR (EGF receptor / ErbB1), activating RAS/MAPK and PI3K/Akt signaling cascades. Promotes keratinocyte and fibroblast proliferation, accelerates wound re-epithelialization, and stimulates collagen and hyaluronic acid production.

Epidermal growth factor (EGF) is an endogenous 53-amino-acid polypeptide that binds the EGF receptor (EGFR) to stimulate cell proliferation, migration, and differentiation in epithelial and mesenchymal cells; it plays a fundamental role in wound healing, skin regeneration, and tissue repair by promoting keratinocyte and fibroblast activation through tyrosine kinase-mediated downstream signaling. EGF activates EGFR tyrosine kinase to initiate PI3K/Akt and MAPK/ERK proliferative signaling cascades; in wound contexts, topically applied recombinant EGF accelerates epithelialization and granulation tissue formation, and injectable EGF has been evaluated for wound bed preparation in diabetic and chronic wounds. Clinical trials of recombinant human EGF for wound healing — including a PubMed-indexed human clinical trial in diabetic foot ulcers — have demonstrated improvements in wound closure and tissue regeneration; recombinant EGF preparations are approved in some countries (Cuba, South Korea) for diabetic wound healing under prescription conditions. Topically applied EGF has no FDA approval in the United States for wound healing or cosmetic applications; recombinant EGF-based wound therapeutics are available internationally under national regulatory approvals outside the US, and EGF is widely incorporated into cosmetic formulations at concentrations where receptor activation and clinical benefit have not been independently validated.